Dermorphin 5mg

Research

Scientific Research on Dermorphin

Dermorphin is a natural opioid peptide originally isolated from the skin secretion of amphibians of the genus Phyllomedusa, especially the species Phyllomedusa sauvagei.

It is a heptapeptide with the sequence:
Tyr–D-Ala–Phe–Gly–Tyr–Pro–Ser–NH₂

An unusual structural aspect is the presence of D-alanine (D-Ala) at the second position — something rare in natural vertebrate peptides — which significantly contributes to its high affinity for opioid receptors.

Dermorphin exhibits analgesic potency far superior to that of morphine in experimental models, due to its high selectivity and affinity for the μ-opioid receptor.

Mechanism of Action

Dermorphin acts as a:
Highly selective μ-opioid receptor (MOR) agonist

Upon binding to the μ-opioid receptor (MOR), which is a G protein-coupled receptor (Gi/o), it triggers:

1. Inhibition of adenylate cyclase
   → Reduction of cyclic AMP (cAMP)
2. Opening of potassium (K⁺) channels
   → Neuronal hyperpolarization
3. Inhibition of voltage-dependent calcium (Ca²⁺) channels
   → Reduction of excitatory neurotransmitter release (substance P, glutamate)

The result is suppression of nociceptive transmission in the central nervous system.

Relative Potency

In animal models:

• May exhibit analgesic potency 30 to 100 times greater than morphine, depending on the route of administration.
• Shows high affinity for the μ-opioid receptor.
• Possesses low relative affinity for δ and κ receptors.

Neurobiological Impacts

Prolonged activation of the μ-opioid receptor can induce:

• Modulation of the mesolimbic dopaminergic pathway
• Potential for tolerance development
• Potential for physical dependence
• Respiratory suppression (in experimental models)

These effects are similar to those observed with classical opioids.

Pharmacokinetics (Experimental Studies)

• Low oral bioavailability (degraded by proteases)
• Experimental administration: intrathecal, intracerebroventricular, or parenteral
• Limited half-life due to enzymatic degradation
• Greater relative stability compared to enkephalins due to the presence of the D-amino acid

Scientifically Investigated Applications

Dermorphin has been studied primarily in:

• Experimental models of acute and chronic pain
• Pharmacological studies of opioid receptor selectivity
• Research on novel, more selective opioid analogs

It is not widely used clinically as an approved medication in most countries.

Potential Risks (Based on Pharmacological Data)

As a potent μ-opioid agonist, potential risks include:

• Respiratory depression
• Profound sedation
• Dependence
• Tolerance
• Constipation
• Bradycardia

These risks are theoretical or observed in experimental models, given its pharmacodynamic similarity to potent opioids.

Relevant Structural Difference

The most notable detail of dermorphin is:
Presence of D-Ala (D-alanine)
→ Increases resistance to enzymatic degradation
→ Increases affinity for the μ receptor
→ Prolongs action compared to endogenous enkephalins

This characteristic has made dermorphin an important molecule in rational opioid design research.

Final Scientific Considerations

Dermorphin is a natural opioid peptide of high potency and selectivity for the μ-opioid receptor. Its primary value lies in pharmacological research and the development of novel opioid analogs with greater selectivity and a potentially differentiated therapeutic profile.

Despite its potency, its clinical use is limited, and its pharmacological profile demands extreme caution due to the inherent risk of intense μ-opioid receptor activation.

Scientific References

Montecucco, C., & De Bernard, M. (1992). Dermorphin and related peptides. Pharmacology & Therapeutics, 55(3), 309–334.

Erspamer, V., Melchiorri, P., Falconieri-Erspamer, G., Negri, L., Corsi, R., Severini, C., Barra, D., Simmaco, M., & Kreil, G. (1989). Deltorphins: a family of naturally occurring peptides with high affinity and selectivity for δ opioid binding sites. Proceedings of the National Academy of Sciences, 86(13), 5188–5192.